

Practitioner's Docket No. MWH-0002US2



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent application of: Chew et al.

for Drug Target Isogenes: Polymorphisms in the Interleukin-4 Receptor Alpha Gene

Assistant Commissioner for Patents
Washington, D.C. 20231

#2
15/0
3/5/02

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
WITHIN THREE MONTHS OF FILING OR
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. section 1.97(b))

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

Date:

9 - November - 2001

Sandra L. Shaner
Signature of Practitioner

Reg. No.: 47,934
Tel. No.: 203-786-3468
Customer No.: 25106

Sandra L. Shaner
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

+

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	
Filing Date	11-09-2001
First Named Inventor	Anne Chew
Group Art Unit	1646
Examiner Name	Prema Mertz
Attorney Docket Number	MWH-0002US2

U.S. PTO

107070802

11/09/01

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS


[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this 

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet <u>1</u> of <u>1</u>		Complete if Known	
		Application Number	
		Filing Date	11-09-2001
		First Named Inventor	Anne Chew
		Group Art Unit	1646
		Examiner Name	Prema Mertz
		Attorney Docket Number	MWH-0002US2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	BA	PRITCHARD MA ET AL., "The Interleukin-4 Receptor gene (IL4R) maps to 16p11.2-16p12.1 in human and to the distal region of mouse chromosome 7," Genomics, Vol. 10 (No. 3), p. 801-806, (July 1991).
	BB	DEICHMANN K. ET AL., "Common Polymorphisms in the Coding Part of the IL4-Receptor Gene," Biochem Biophys Res Comm, Academic Press, Vol. 231 (No. 3), p. 696-697, (February 24, 1997).
	BC	KURANA HERSHEY GK ET AL., "The Associations of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor," New Eng. J. Med, Vol. 337 (No. 24), p. 1720-25, (December 11, 1997).
	BD	IMANI F ET AL., "Interleukin-4 (IL-4) Induces Phosphatidylinositol 3-kinase (p85) Dephosphorylation. Implications for the role of SHP1-1 in the IL-4-induced signals in human B cells," J. Biol. Chem., Vol. 272 (no. 12) p. 7927-7931, (March 21, 1997).
	BE	MITSUYASU H. ET AL., "Ile50Val variant of IL4Ralpha upregulates IgE synthesis and associates with atopic asthma," Nat Genet, Vol. 19 (No. 2), p. 119-120, (June 1998).
	BF	BUETOW KH ET AL., "Reliable identification of large numbers of candidate SNPs from public EST data," Nat Genet, Vol. 21 (No. 3), p. 323-325, (March 1999).
	BG	KANEMITSU S. ET AL., " Association of Interleukin-4 receptor and Interleukin-4 promoter gene polymorphisms with systemic lupus erythematosus," Arthritis Rheum, American College of Rheumatology, Vol. 42 (No. 6), p. 1298-1300, (June 1999).
	BH	KRUSE S. ET AL., "The Polymorphisms S503P and Q576R in the interleukin-4 receptor alpha gene are associated with atopy and influence the signal transduction," Immunology, Blackwell Science Ltd, Vol. 96 (No. 3), p. 365-71, (March 1999).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.